Publications

Abstract Sarcopenic obesity (SO) is a phenotype that gained interest in the past two decades. It combines an increase in fat deposition with a reduction of muscle mass and strength. Till now SO is not included among routine assessment in weight-management setting for obesity. In this opinion paper we aim to explain the rational behind the clinical implication of the inclusion of screening for SO at baseline obesity treatments. First of all, SO is a prevalent condition in weight-loss settings; in addition to that, it is strongly associated with weight-related diseases and comorbidities. Moreover baseline SO is associated poorer physical fitness, reduced resting energy expenditure and more sedentary lifestyle. Finally, it predicts poorer clinical outcomes of obesity treatment such as the early dropout and the lack of weight-loss maintenance in the long term. In here stems the clinical implication to include the screening of SO as a routine assessment at baseline in patients with obesity willing to start weight management programs.